MX2009012922A - Vacunacion intradermica de un peptido del virus del papiloma humano. - Google Patents

Vacunacion intradermica de un peptido del virus del papiloma humano.

Info

Publication number
MX2009012922A
MX2009012922A MX2009012922A MX2009012922A MX2009012922A MX 2009012922 A MX2009012922 A MX 2009012922A MX 2009012922 A MX2009012922 A MX 2009012922A MX 2009012922 A MX2009012922 A MX 2009012922A MX 2009012922 A MX2009012922 A MX 2009012922A
Authority
MX
Mexico
Prior art keywords
intradermal
peptide vaccination
hpv peptide
hpv
medicament
Prior art date
Application number
MX2009012922A
Other languages
English (en)
Spanish (es)
Inventor
Sjoerd Henricus Van Der Burg
Gemma G Kenter
Cornelis Johannes Maria Melief
Original Assignee
Academisch Ziekenhuis Leiden H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden H filed Critical Academisch Ziekenhuis Leiden H
Publication of MX2009012922A publication Critical patent/MX2009012922A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MX2009012922A 2007-05-31 2008-05-27 Vacunacion intradermica de un peptido del virus del papiloma humano. MX2009012922A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94107007P 2007-05-31 2007-05-31
EP07109287 2007-05-31
PCT/NL2008/050315 WO2009002159A2 (en) 2007-05-31 2008-05-27 Intradermal hpv peptide vaccination

Publications (1)

Publication Number Publication Date
MX2009012922A true MX2009012922A (es) 2010-07-05

Family

ID=38477016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012922A MX2009012922A (es) 2007-05-31 2008-05-27 Vacunacion intradermica de un peptido del virus del papiloma humano.

Country Status (10)

Country Link
US (2) US9562075B2 (enExample)
EP (1) EP2155240B1 (enExample)
JP (2) JP2010530362A (enExample)
CN (1) CN101795705A (enExample)
AU (1) AU2008269721B2 (enExample)
BR (1) BRPI0812311A8 (enExample)
CA (1) CA2688589A1 (enExample)
ES (1) ES2482192T3 (enExample)
MX (1) MX2009012922A (enExample)
WO (1) WO2009002159A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468763B1 (en) * 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
CA2731444A1 (en) * 2008-09-02 2010-03-11 Antigen Express, Inc. Human papillomavirus / li-key hybrids and methods of use
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスBionor Immuno As ペプチド骨格設計
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
JP7092662B2 (ja) 2015-10-30 2022-06-28 チルドレンズ ナショナル メディカル センター ナイーブt細胞集団からのhpv抗原特異的t細胞の生成
CN108430505A (zh) 2015-11-18 2018-08-21 免疫疫苗技术有限公司 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
US11524063B2 (en) * 2017-11-15 2022-12-13 Arizona Board Of Regents On Behalf Of Arizona State University Materials and methods relating to immunogenic epitopes from human papillomavirus
CA3093826A1 (en) * 2018-03-12 2019-09-19 Sqz Biotechnologies Company Methods for treating hpv-associated diseases
EP3765068A2 (en) * 2018-03-12 2021-01-20 SQZ Biotechnologies Company Intracellular delivery of biomolecules to modify immune response
US11065317B2 (en) * 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
JP2024503277A (ja) * 2020-12-29 2024-01-25 スクイーズ バイオテクノロジーズ カンパニー 活性化抗原担体の製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5932412A (en) 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
DE9106105U1 (de) * 1991-05-17 1991-09-26 Behringwerke Ag, 3550 Marburg Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
JP2000503003A (ja) * 1995-12-22 2000-03-14 イムノメディクス,インコーポレイテッド 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
AU765822B2 (en) 1998-05-23 2003-10-02 Leiden University Medical Center CD40 binding molecules and CTL peptides for treating tumors
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6641994B2 (en) 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
CA2431500C (en) * 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
WO2003008649A1 (en) * 2001-07-20 2003-01-30 Board Of Regents, The University Of Texas System Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
US6884605B2 (en) * 2001-08-09 2005-04-26 Board Of Trustees Of The University Of Arkansas Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
EP1708745B1 (en) 2003-12-23 2012-04-18 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US20090028874A1 (en) * 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
DE602006021408D1 (de) * 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
BRPI0812311A8 (pt) 2019-02-05
JP2014185179A (ja) 2014-10-02
US20170143818A1 (en) 2017-05-25
WO2009002159A3 (en) 2009-02-12
ES2482192T3 (es) 2014-08-01
AU2008269721A1 (en) 2008-12-31
EP2155240B1 (en) 2014-04-30
US9562075B2 (en) 2017-02-07
JP5888823B2 (ja) 2016-03-22
US20100196353A1 (en) 2010-08-05
CA2688589A1 (en) 2008-12-31
WO2009002159A2 (en) 2008-12-31
AU2008269721B2 (en) 2013-01-10
CN101795705A (zh) 2010-08-04
EP2155240A2 (en) 2010-02-24
JP2010530362A (ja) 2010-09-09
BRPI0812311A2 (pt) 2014-10-29

Similar Documents

Publication Publication Date Title
MX2009012922A (es) Vacunacion intradermica de un peptido del virus del papiloma humano.
WO2008087190A3 (en) Use of peptides in combination with surgical intervention for the treatment of obesity
TW200744642A (en) Novel peptides for use in the treatment of obesity
WO2008087186A3 (en) Peptides for use in the treatment of obesity
IL201479A (en) Use of tapentadol for the preparation of pain medication
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MY162741A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin D1
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MY167234A (en) Novel glucagon analogues
MX2012013731A (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2008087188A3 (en) Peptides for use in the treatment of obesity
PL2081910T3 (pl) Nowe związki
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
NZ594347A (en) Antibodies against human tweak and uses thereof
MX2011008261A (es) FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1.
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
MX350145B (es) Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
WO2009120022A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
NZ606236A (en) Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
MX2012000541A (es) Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos.
EA201000738A1 (ru) Медицинское применение 3-(2,2,2-триметилгидразиниум)пропионат гидрофумарата и дигидрофосфата
WO2004101780A3 (en) Heparanase-derived peptides for vaccination of tumor patients

Legal Events

Date Code Title Description
FG Grant or registration